PHOENIX, AZ--(Marketwired - Jul 23, 2015) - Insys Therapeutics, Inc. (
Following the release of the financial results, Michael L. Babich, President and Chief Executive Officer, and Darryl S. Baker, Chief Financial Officer, will host a conference call as follows:
| Date | Thursday, August 6, 2015 | |
| Time | 10:00 a.m. EDT | |
| Toll free (U.S.) | 800-918-9577 | |
| International | 212-271-4651 | |
| Webcast (live and replay) | www.insysrx.com under the 'Investor Relations' section. |
A replay of the conference call will be available for two weeks after the call's completion by dialing (800) 633-8284 (U.S.) or (402) 977-9140 (International). The conference ID for the replay is 21772681. The archived webcast will be available for 30 days via the aforementioned URL.
About Insys Therapeutics, Inc.
Insys Therapeutics is a specialty pharmaceutical company that develops and commercializes innovative drugs and novel drug delivery systems of therapeutic molecules that improve the quality of life of patients. Using proprietary sublingual spray technology and capabilities to develop pharmaceutical cannabinoids, Insys addresses the clinical shortcomings of existing commercial products. Insys currently markets two products: Subsys®, which is sublingual Fentanyl spray for breakthrough cancer pain, and a generic version of Dronabinol (THC) capsules. The Company's recently submitted a New Drug Application to the U.S. Food and Drug Administration for Dronabinol Oral Solution, a proprietary, orally administered liquid formulation of dronabinol that Insys believes has distinct advantages over the current formulation of dronabinol in soft gel capsule. Insys is developing a pipeline of sublingual sprays, as well as pharmaceutical cannabidiol.
Subsys® is a registered trademark of Insys Therapeutics, Inc.